---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000179"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:41:35.080306+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Intellia sets 2023 milestones: NTLA-2001 IND mid-year, $1.3B cash

## Summary
- Cash, cash equivalents and marketable securities ~$1.3B as of Dec 31, 2022.
- NTLA-2001 IND submission mid-2023 for global pivotal trial in ATTR-CM; study start by year-end.
- NTLA-2002 (HAE) Phase 2 study initiation and IND submission in 1H 2023.
- NTLA-3001 (gene insertion for AATD) IND or equivalent filing in 2H 2023.
- Additional clinical data from NTLA-2001 and NTLA-2002 studies expected in 2023.

## SEC filing metadata
- accession: 0000950170-23-000179
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017023000179/0000950170-23-000179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017023000179/ntla-20230105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000179
- JSON: https://secwatch.observer/filing/0000950170-23-000179.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000179.txt

## Key facts
- Earnings Releases
  Intellia Therapeutics, Inc. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2022.
  - Period: the fourth quarter and fiscal year ended December 31, 2022
  - Result: preliminary results
  source text: Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2022, Intellia Therapeutics, Inc. (the “Company”) announced on January 5, 2023, that it expects to report that it had approximately $1.3 billion of cash, cash equivalents and marketable securities as of December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017023000179/0000950170-23-000179-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.